DOCSLIB.ORG

Solitary Fibrous Tumor: Integration of Clinical, Morphologic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Solitary Fibrous Tumor: Integration of Clinical, Morphologic International Journal of Molecular Sciences Article Solitary Fibrous Tumor: Integration of Clinical, Morphologic, Immunohistochemical and Molecular Findings in Risk Stratification and Classification May Better Predict Patient Outcome Isidro Machado 1,2,*, María Gema Nieto Morales 3 , Julia Cruz 1, Javier Lavernia 4, Francisco Giner 5, Samuel Navarro 6, Antonio Ferrandez 6 and Antonio Llombart-Bosch 6 1 Pathology Department, Instituto Valenciano de Oncología, 46009 Valencia, Spain; jcruz@fivo.org 2 Patologika Laboratory, Pathology Department, Hospital Quiron-Salud, 46009 Valencia, Spain 3 Zoology Department, University of Valencia, 46009 Valencia, Spain; [email protected] 4 Department of Oncology, Instituto Valenciano de Oncología, 46009 Valencia, Spain; [email protected] 5 Pathology Department, University Hospital “La Fe”, 46009 Valencia, Spain; [email protected] 6 Pathology Department, University of Valencia, 46009 Valencia, Spain; [email protected] (S.N.); [email protected] (A.F.); [email protected] (A.L.-B.) * Correspondence: [email protected] Abstract: Although solitary fibrous tumors (SFTs) have an unpredictable evolution, some specific Citation: Machado, I.; Nieto Morales, clinicopathologic factors have been associated with the final outcome. We retrieved clinical, patholog- M.G.; Cruz, J.; Lavernia, J.; Giner, F.; ical and molecular data of 97 patients with a histological diagnosis of SFT and Signal transducer and Navarro, S.; Ferrandez, A.; activator of transcription 6 (STAT6) positivity. We retrospectively studied the pathological factors Llombart-Bosch, A. Solitary Fibrous predictive of recurrence/metastasis and compared them with the clinical outcome. A wide immuno- Tumor: Integration of Clinical, histochemical study and molecular analysis to detect NAB2/STAT6 gene fusion, tumor protein-53 Morphologic, Immunohistochemical (TP53) and/or (telomerase reverse transcriptase) TERT promotor mutation were performed. The and Molecular Findings in Risk risk of metastasis was calculated using the Demicco risk stratification system (RSS). The results were Stratification and Classification May combined and examined to assess the accuracy of risk stratification and classification. The most Better Predict Patient Outcome. Int. J. common location was in non-extremities; 66% were located in soft tissue or subcutaneous areas and Mol. Sci. 2021, 22, 9423. https:// 92.8% in deep locations. On microscopic analysis, 38.1% of tumors revealed hypercellularity with a doi.org/10.3390/ijms22179423 predominant patternless and/or hemangiopericytic growth pattern; 13.4% had ≥4 mitoses/10HPF; Academic Editor: Maria 16.5% showed necrosis, and almost half the tumors showed at least focal myxoid areas. Dedif- Grazia Cifone ferentiation was observed in three tumors. Immunomarker expression in SFTs was as follows: CD34 92.9%, CD99 57.1%, Bcl2 67.9%, neuroendocrine markers (at least 1) 25.7%, Desmin 14.3%, Received: 12 July 2021 CK(AE1/AE3) 3%, Apoptotic Protease Activating Factor (APAF-1) 87% and finally Ki-67 ≥10% Accepted: 26 August 2021 in 14.4%. The NAB2/STAT6 gene fusion was detected in 50 tumors. After a median follow-up of Published: 30 August 2021 90 months, 9.3% recurred, 11.3% metastasized, 10.3% died of disease and 76.2% were free of disease. TERT mutations were detected in 40.6% of the SFTs; the TP53 mutation was detected in 17%, and Publisher’s Note: MDPI stays neutral only 9.3% showed both mutations. According to the Demicco RSS, 6.1%, 11.3% and 82.4% of the with regard to jurisdictional claims in tumors were classified as high, intermediate or low-risk of metastasis, respectively. All high-risk published maps and institutional affil- tumors had ≥4 mitoses/10HPF, necrosis, Ki-67 ≥ 10, HTER and/or TP53 mutation and poor evo- iations. lution. The intermediate risk SFTs with worse evolution displayed the HTER mutation. Almost all low-risk tumors had a favorable evolution, although four showed at least one adverse factor (Ki-67 ≥ 10, ≥4 mitoses/10HPF or high tumor size) and had a worse evolution. An integration of clinical, morphologic, immunohistochemical and molecular findings may improve risk stratification and Copyright: © 2021 by the authors. classification and better predict patient outcome. The unfavorable course seems to be more frequent Licensee MDPI, Basel, Switzerland. in high-risk SFTs, although it is not exceptional in low-risk SFTs either; hence, a long-term follow-up This article is an open access article is required independently of the assigned risk stratification score. The inclusion of molecular findings distributed under the terms and in risk stratification systems could improve the precision in the classification of SFTs, especially conditions of the Creative Commons Attribution (CC BY) license (https:// those of intermediate risk. Future studies will be required to determine the most effective way to creativecommons.org/licenses/by/ incorporate molecular analyses into RSS on SFTs. The coexistence of several adverse factors such 4.0/). Int. J. Mol. Sci. 2021, 22, 9423. https://doi.org/10.3390/ijms22179423 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, 9423 2 of 14 as ≥4 mitoses/10HPF, necrosis, Ki-67 ≥ 10%, mutations in HTER and/or p53 may suggest a closer clinical follow-up regardless of the histological appearance of the tumor. Keywords: solitary fibrous tumor; risk stratification systems; STAT6; APAF-1; HTER mutation; p53 mutation 1. Introduction Solitary fibrous tumors (SFTs) are mesenchymal neoplasms that can occur at any location, especially pleural, meningeal or extrapleural sites. Location in limbs is infre- quent [1–40]. The evolution of SFTs is often uncertain [2–10]. Although most cases evolve favorably, a small group can progress towards dissemination, generally pulmonary, as well as other locations, and will lead to patient death in the absence of effective treatments [1–19]. Thus, valid and reproducible tools should be developed in order to design risk-tailored treatment and risk-adjusted follow-up. A patternless and hemangiopericytic growth with variably fibrosis and collagenous de- posits are characteristic, but SFTs can show many faces, including round cells, giant-cells, myx- oid areas, pleomorphic pattern, fat-forming tumors and dedifferentiated forms [1–5,15–25]. Strong and diffuse nuclear immunoreactivity for Signal transducer and activator of transcription 6 (STAT6) is almost always diagnosed in SFTs, and CD34, Bcl-2 and CD99 immunoexpression is common [1–25]. Aberrant epithelial, muscular or neuroendocrine marker expression has been described which may lead to confusion with other tumors that share a similar morphology [15–25,36]. The fusion gene NAB2/STAT6 and its variants confirm a diagnosis of SFT in those cases with unconvincing STAT6 immunoreactivity, and specific gene fusions have been related to prognosis and tumor location [6–14,26–40]. STAT6 nuclear expression is not exclusive to SFTs and has also been reported in dedifferen- tiated liposarcoma, glioma-associated oncogene homolog 1 (GLI1)-amplified tumor, Kaposi sarcoma and Hodgkin as well non-Hodgkin lymphomas [6,12–25,36–40]. Several risk-stratification systems (RSS) have been described [1–5], although the Demicco et al. RSS seems to be the most widely implemented [1,2,14]. While most SFTs categorized as low-risk by the Demicco system follow an apparently benign course, some cases may have late relapse or metastases; hence, the RSS is not perfectly specific in predicting the evolution in all cases [1,2,14]. In addition, molecular results have not so far been included in any of the current RSS [1,2,14]. Recently, loss of Apoptotic Protease Activating Factor (APAF-1) expression has been associated with poor prognosis in SFTs, but these findings need to be confirmed in larger series [41]. We have previously published a small series of SFTs with at least one histological factor associated with aggressive behavior and explored the correlation between the adverse histological findings and molecular profile with tumor behavior [42]. The main goal of the present study was to confirm our previous results including additional tumors, mainly SFTs categorized as low-risk by Demicco et al. [1,2] and correlate the clinical, histological and immunohistochemical findings, TP53 mutational status and TERT promotor mutational status with clinical outcome. 2. Results 2.1. Clinicopathological and Histopathological Findings The clinicopathological and follow-up data are shown in Tables1 and2. The histologic findings are shown in Figure1 and summarized in Table3. The median follow-up was 90 months. In the microscopic analysis, 38.1% of tumors revealed hypercellularity with a predominant patternless and/or hemangiopericytic growth pattern (Figure1); 13.4% had ≥4 mitoses/10HPF; 16.5% showed necrosis and myxoid areas were frequent (Figure1). Int. J. Mol. Sci. 2021, 22, 9423 3 of 14 Dedifferentiation was observed in three tumors (Figure1). Rare histological patterns were found in sporadic cases (Figure1). 2.2. Immunohistochemistry Results The representative status of the immunohistochemical profile is shown in (Figure2 ) and summarized in Table4. All tumors were diffusely positive for STAT6 (Figure2C), CD34, CD99 (Figure2A,B) and Bcl2 which were frequent, and neuroendocrine markers (at least 1), Desmin, CK(AE1/AE3) were detected sporadically. APAF-1 immunoexpression was detected in 87% of the SFTs, and Ki-67 ≥ 10 was found in 14.4% of the tumors. Table 1. Solitary fibrous tumor clinical data (N = 97). Variables N % Age <55 52 53.6 ≥55 45 46.4 Gender Male 46 47.4 Female 51 52.6 Tumor location Limbs 6 6.2 Not limbs 91 93.8 Tumor location Soft tissue and/or subcutaneous 64 66 tissues Pleural 19 19.6 Visceral 12 12.3 Meningeal 2 2.1 Tumor size <5 cm 38 39.1 5–<10 cm 36 37.1 10–<15 cm 12 12.4 ≥15 cm 11 11.4 Location Deep 90 92.8 Superficial 7 7.2 Surgery Yes 94 97 No 3 3 Radiotherapy Yes 4 4 No 93 96 Chemotherapy Yes 7 7.2 No 90 92.8 Int. J. Mol. Sci. 2021, 22, 9423 4 of 14 Table 2.
Load more

Recommended publications
  • Download This PDF File
    University Journal of Pre and Para Clinical Sciences ISSN 2455–2879 2017, Vol.3(4) SOLITARY FIBROUS TUMOR OF LUNG MIMICKING AS LUNG METASTASIS IN A KNOWN CASE OF WILMS TUMOR. SELVI Department of Pathology, MADRAS MEDICAL COLLEGE AND GOVERNMENT GENERAL HOSPITAL Abstract : Solitary fibrous tumor is the most common benign mesenchymal pleural neoplasm. It also affects mediastinum, lungs and other organs of any individual from young children to adults without sex predilection. Here we report a case of 4 years old child, a known case of treated Wilms tumor, presenting with a Solitary fibrous tumor of lung that was clinically mistaken for a lung metastasis. Ametachronous benign tumor occurring after a malignant tumor is a rare entity and whether it could bea part of any syndrome could not be established due to lack of molecular diagnostic studies. Keyword :Metachronous tumor Wilms tumor - Solitary fibrous tumor Lung. FIG 2 CT Image Axial View Mass Lesion R Lung INTRODUCTION: As the patient is a known case of Wilms tumor operated one year back, a clinical diagnosis ofmetastatic Solitary Fibrous Tumor (SFT) is a rare benign neoplasm Wilms tumor was considered. Right thoracotomy was done and arising from pleura, mediastinum and the tumor was seen as a huge pleuro pulmonary mass and the lungs and virtually at any anatomic location. The tumor is most tumor was excised. The child gave a past history of being common in patients between 20 and 70years old. Hence we operated for Wilm’s tumor – Triphasic type, one year back, report a rare case of pulmonary SFT in 4year old child, who was followed by chemo and radiotherapy for the same ailment.
    [Show full text]
  • Soft Tissue Cytopathology: a Practical Approach Liron Pantanowitz, MD
    4/1/2020 Soft Tissue Cytopathology: A Practical Approach Liron Pantanowitz, MD Department of Pathology University of Pittsburgh Medical Center [email protected] What does the clinician want to know? • Is the lesion of mesenchymal origin or not? • Is it begin or malignant? • If it is malignant: – Is it a small round cell tumor & if so what type? – Is this soft tissue neoplasm of low or high‐grade? Practical diagnostic categories used in soft tissue cytopathology 1 4/1/2020 Practical approach to interpret FNA of soft tissue lesions involves: 1. Predominant cell type present 2. Background pattern recognition Cell Type Stroma • Lipomatous • Myxoid • Spindle cells • Other • Giant cells • Round cells • Epithelioid • Pleomorphic Lipomatous Spindle cell Small round cell Fibrolipoma Leiomyosarcoma Ewing sarcoma Myxoid Epithelioid Pleomorphic Myxoid sarcoma Clear cell sarcoma Pleomorphic sarcoma 2 4/1/2020 CASE #1 • 45yr Man • Thigh mass (fatty) • CNB with TP (DQ stain) DQ Mag 20x ALT –Floret cells 3 4/1/2020 Adipocytic Lesions • Lipoma ‐ most common soft tissue neoplasm • Liposarcoma ‐ most common adult soft tissue sarcoma • Benign features: – Large, univacuolated adipocytes of uniform size – Small, bland nuclei without atypia • Malignant features: – Lipoblasts, pleomorphic giant cells or round cells – Vascular myxoid stroma • Pitfalls: Lipophages & pseudo‐lipoblasts • Fat easily destroyed (oil globules) & lost with preparation Lipoma & Variants . Angiolipoma (prominent vessels) . Myolipoma (smooth muscle) . Angiomyolipoma (vessels + smooth muscle) . Myelolipoma (hematopoietic elements) . Chondroid lipoma (chondromyxoid matrix) . Spindle cell lipoma (CD34+ spindle cells) . Pleomorphic lipoma . Intramuscular lipoma Lipoma 4 4/1/2020 Angiolipoma Myelolipoma Lipoblasts • Typically multivacuolated • Can be monovacuolated • Hyperchromatic nuclei • Irregular (scalloped) nuclei • Nucleoli not typically seen 5 4/1/2020 WD liposarcoma Layfield et al.
    [Show full text]
  • Fascin‑1 Is Associated with Recurrence in Solitary Fibrous Tumor/Hemangiopericytoma
    MOLECULAR AND CLINICAL ONCOLOGY 15: 199, 2021 Fascin‑1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma YUMIKO YAMAMOTO1, YOSHIHIRO HAYASHI2, HIDEYUKI SAKAKI3 and ICHIRO MURAKAMI1,4 1Department of Diagnostic Pathology, Kochi University Hospital, Kochi University; 2Equipment of Support Planning Office, Kochi University, Nankoku, Kochi 783‑8505; 3Department of Nutritional Sciences for Well‑being Health, Kansai University of Welfare Sciences, Kashiwa, Osaka 582‑0026; 4Department of Pathology, School of Medicine, Kochi University, Nankoku, Kochi 783‑8505, Japan Received March 31, 2021; Accepted July 15, 2021 DOI: 10.3892/mco.2021.2361 Abstract. Fascin‑1, an actin‑bundling protein, is associated epithelial membrane antigen (1‑5). This lack of specificity in with poor prognosis in patients with various types of SFT/HPC occasionally caused problems in differentiating human carcinoma. However, research is limited on the role them from other tumors that are immunohistologically alike of fascin‑1 in sarcoma. Solitary fibrous tumor (SFT) and them. In 2013, three groups reported that SFT and HPC have hemangiopericytoma (HPC) are rare sarcomas derived from the a common gene fusion between NGFI‑A‑binding protein 2 mesenchyme. Although the prognosis of SFT/HPC is generally (NAB2) and signal transducer and activator of transcription 6 favorable, fatalities are possible with repeated recurrence (STAT6) (1,6,7). Thereafter, STAT6, which has dual functions and distant metastasis. The current study included a total of as a signal transducer and as transcription activator in SFT 20 Japanese patients, who were diagnosed with SFT/HPC and and HPC, was recognized as the highly sensitive and specific underwent surgery at Kochi University Hospital from January immunohistochemical marker for SFT/HPC (2‑5,8‑11).
    [Show full text]
  • Solitary Fibrous Tumor of the Pleura: Histology, CT Scan Images and Review of Literature Over the Last Twenty Years
    DOI: 10.26717/BJSTR.2017.01.000150 Flavio Colaut. ISSN: 2574-1241 Biomed J Sci & Tech Res Case Report Open Access Solitary Fibrous Tumor of the Pleura: Histology, CT Scan Images and Review of Literature over the Last Twenty Years Giulia Bora1, Flavio Colaut2*, Gianni Segato3, Luisa Delsedime4 and Alberto Oliaro1 1Department of Thoracic Surgery, University of Turin, Italy 2Department of General Surgery and Thoracic, City Hospital , Montebelluna, (Treviso), Italy 3Department of General Surgery, S. Bortolo City Hospital, Vicenza, Italy 4Department of Pathology, University of Turin, Italy Received: June 14, 2017; Published: June 26, 2017 *Corresponding author: Flavio Colaut, Department of General Surgery, City Hospital Montebelluna, Thoracic City Hospital, via Montegrappa 1, 31044 Montebelluna (Treviso), Italy, Tel: ; Fax: 0499367643; Email: Introduction Literature up to 800 cases [1-3] have been reported, and these in case of recurrence [10,16,17]. In less than 5% of patients with Solitary fibrous tumor of the pleura is a rare neoplasm. In numbers show its rarity, despite of mesotheliomas, the most pleural SFPTs an increase of insulin-like factor II type occur and this causes refractory to therapy hypoglycaemia (Doege-Potter syndrome) similar in both sexes and there no differences in both benign and [10,18,19]. The incidence of Doege-Potter syndrome in SFPT is tumors represented. Males and females are equal distributed asbestos, tobacco or others environmental agents, were found for and the same is true for age. No correlation with exposure to malignantSome patients forms. may also present gynecomastia or galactorrhoea its development. Solitary fibrous tumor of the pleura occurs as localized neoplasms of the pleura and was initially classified as microscope and immunohistochemistry, has been possible [1].
    [Show full text]
  • 1 Effective January 1, 2018 ICD‐O‐3 Codes, Behaviors and Terms Are Site‐Specific Alpha Order Last Updat
    Effective January 1, 2018 ICD‐O‐3 codes, behaviors and terms are site‐specific Alpha Order Last updated 8/22/18 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code New Term 8551/3 Acinar adenocarcinoma (C34. _) Y Lung primaries diagnosed prior to 1/1/2018 use code 8550/3 For prostate (all years) see 8140/3 New Term 8140/3 Acinar adenocarcinoma (C61.9 ONLY) Y For prostate only, do not use 8550/3 New Term 8572/3 Acinar adenocarcinoma, sarcomatoid (C61.9) Y New Term 8550/3 Acinar cell carcinoma Y Excludes C61.9‐ see 8140/3 New Term 8316/3 Acquired cystic disease‐associated renal cell carcinoma (RCC) Y (C64.9) New 8158/1 ACTH‐producing tumor N code/term New Term 8574/3 Adenocarcinoma admixed with neuroendocrine carcinoma (C53. _) Y Behavior 8253/2 Adenocarcinoma in situ, mucinous (C34. _) Y Important note: lung Code/term primaries ONLY: For cases diagnosed 1/1/2018 forward do not use code 8480 (mucinous adenocarcinoma) for in‐ situ adenocarcinoma, mucinous or invasive mucinous adenocarcinoma. 1 Status ICD‐O‐3 Term Reportable Comments Morphology Y/N Code Behavior 8250/2 Adenocarcinoma in situ, non‐mucinous (C34. _) Y code/term New Term 9110/3 Adenocarcinoma of rete ovarii (C56.9) Y New 8163/3 Adenocarcinoma, pancreatobiliary‐type (C24.1) Y Cases diagnosed prior to code/term 1/1/2018 use code 8255/3 Behavior 8983/3 Adenomyoepithelioma with carcinoma (C50. _) Y Code/term New Term 8620/3 Adult granulosa cell tumor (C56.9 ONLY) N Not reportable for 2018 cases New Term 9401/3 Anaplastic astrocytoma, IDH‐mutant (C71.
    [Show full text]
  • The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
    Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events
    [Show full text]
  • Solitary Fibrous Tumor of the Liver
    international journal of surgery 6 (2008) 396–399 www.theijs.com Review Solitary fibrous tumor of the liver: Report of a rare case and review of the literature M.V. Perini*, P. Herman, L.A.C. D’Albuquerque, W.A. Saad University of Sao Paulo School of Medicine, Department of Gastroenterology, Digestive Surgery Division, Sa˜o Paulo, Sa˜o Paulo, Brazil article info abstract Article history: Solitary fibrous tumor of the liver is extremely rare, with only 38 cases reported in the lit- Received 15 September 2007 erature. We present one case of a SFT originating from the caudate lobe of the liver, treated Received in revised form 30 by surgical resection and review the previous reported cases. September 2007 ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved. Accepted 3 October 2007 Published online 25 October 2007 Keywords: Fibroma Liver neoplasm Surgery 1. Introduction 2. Case report Solitary fibrous tumors (SFTs) also known as localized fibrous A 40-year-old woman with six months history of mild upper mesothelioma, localized fibroma, localized fibrous tumor or abdominal pain was referred for evaluation. At physical and solitary fibrous tumor, are rare tumors with a controversial or- laboratory examination no abnormality was found. Ultrasound 1,2 igin. Most often the origin is the pleura but occasionally the (US) and computed tomographic scan (CT) disclosed a big mass, mediastinum, peritoneum or mesentery. SFTs of the liver are 10 cm in diameter, hyperechoic at US and hypodense at CT, extremely rare and in a literature review, only 38 cases have involving the caudate lobe and segments II and III of the 1–29 been reported (Table 1).
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Solitary Fibrous Tumor of the Kidney - a Report of Two Cases with Review of Literature
    The Korean Journal of Pathology 2010; 44: 420-5 DOI: 10.4132/KoreanJPathol.2010.44.4.420 Solitary Fibrous Tumor of the Kidney - A Report of Two Cases with Review of Literature - Sun A Kim∙Jung Eun Hwang Solitary fibrous tumor (SFT) is a benign mesenchymal neoplasm usually occurring in the pleu- Jae Y. Ro∙Kyung-Ja Cho ra. Kidney is one of the rarest sites for SFT. We report here on two cases of renal SFT found Cheryn Song1∙Mi-Jung Kim in 30-year-old and 33-year-old men with review of the literatures. Both cases manifested as well-enhanced solid masses in kidney and radical nephrectomies were done. The tumors con- sisted of bland-looking spindle cells arranged in short, ill-defined fascicles and storiform pat- Departments of Pathology and 1Urology, Asan Medical Center, University of Ulsan tern with characteristic hemangiopericytoma-like blood vessels. The tumor cells were strongly College of Medicine, Seoul, Korea positive for CD34 and CD99, focally positive for bcl-2, and negative for cytokeratin and human melanoma black-45 on immunohistochemical stainings. Possibility of SFT should be consid- Received : April 15, 2009 ered in the differential diagnosis of a renal mass which consists of benign-looking spindle cells Accepted : August 12, 2009 and hemangiopericytomatous blood vessels. Immunohistochemical staining for CD34 is essen- tial to confirm the renal solitary fibrous tumor. Corresponding Author Mi-Jung Kim, M.D. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap 2-dong, Songpa-gu, Seoul 138-736, Korea Tel: 82-2-3010-4557 Fax: 82-2-472-7898 E-mail: [email protected] Key Words : Solitary fibrous tumor; Kidney; Immunohistochemistry Solitary fibrous tumor (SFT) is a relatively rare spindle cell strong early enhancement and rapid washout pattern in contrast- neoplasm usually occurring in the pleura.
    [Show full text]
  • Solitary Fibrous Tumors: Loss of Chimeric Protein Expression and Genomic Instability Mark Dedifferentiation
    Modern Pathology (2015) 28, 1074–1083 1074 © 2015 USCAP, Inc All rights reserved 0893-3952/15 $32.00 Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation Gian P Dagrada1, Rosalin D Spagnuolo1, Valentina Mauro1,6, Elena Tamborini2, Luca Cesana2, Alessandro Gronchi3, Silvia Stacchiotti4, Marco A Pierotti5,7, Tiziana Negri1,8 and Silvana Pilotti1,8 1Laboratory of Experimental Molecular Pathology, Department of Diagnostic Pathology and Laboratory, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 2Department of Diagnostic Pathology and Laboratory, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 3Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 4Adult Mesenchymal Tumor Medical Oncology Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and 5Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Solitary fibrous tumors, which are characterized by their broad morphological spectrum and unpredictable behavior, are rare mesenchymal neoplasias that are currently divided into three main variants that have the NAB2-STAT6 gene fusion as their unifying molecular lesion: usual, malignant and dedifferentiated solitary fibrous tumors. The aims of this study were to validate molecular and immunohistochemical/biochemical approaches to diagnose the range of solitary fibrous tumors by focusing on the dedifferentiated variant, and to reveal the genetic events associated with dedifferentiation by integrating the findings of array comparative genomic hybridization. We studied 29 usual, malignant and dedifferentiated solitary fibrous tumors from 24 patients (including paired samples from five patients whose tumors progressed to the dedifferentiated form) by means of STAT6 immunohistochemistry and (when frozen material was available) reverse-transcriptase polymerase chain reaction and biochemistry.
    [Show full text]
  • Malignant Solitary Fibrous Tumor with Heterologous Rhabdomyosarcomatous Differentiation: a Case Report
    Journal of Pathology and Translational Medicine 2017; 51: 171-175 ▒ CASE STUDY ▒ https://doi.org/10.4132/jptm.2016.08.29 Malignant Solitary Fibrous Tumor with Heterologous Rhabdomyosarcomatous Differentiation: A Case Report Jeong-Hwa Kwon · Joon Seon Song Malignant solitary fibrous tumor (MSFT) is a well-described entity, from which heterologous differ- Hye Won Jung1 · Jong-Seok Lee2 entiation is extremely rare. We encountered a case of MSFT with rhabdomyosarcomatous differ- Kyung-Ja Cho entiation in a 56-year-old man. This patient presented with a large mass in his posterior thigh. He had been treated with chemoradiation for sarcoma involving the cervical spine, right femoral head, and both lungs 6 months earlier. A wide excision was performed. The mass measured 10.6 Department of Pathology, 1Department of Radiology, Research Institute of Radiology, cm and showed a fish-flesh cut surface with necrotic foci. Microscopically, the tumor showed 2Department of Orthopedic Surgery, Asan heterogeneous cellularity with a hemangiopericytic vascular pattern. A hypercellular area showed Medical Center, University of Ulsan College of spindle cells or epithelioid cells with high mitotic activity (63/10 high-power fields) and immunore- Medicine, Seoul, Korea activity for CD34 and CD99. A hypocellular area and a cystic area showed pleomorphic rhabdoid cells with immunoreactivity for desmin and myogenin. This is a report of a rare case of MSFT with Received: May 19, 2016 rhabdomyosarcomatous differentiation and presents new histologic features of MSFT.
    [Show full text]
  • Immunohistochemistry in Diagnosis of Soft Tissue Tumours Cyril Fisher
    Immunohistochemistry in Diagnosis of Soft Tissue Tumours Cyril Fisher To cite this version: Cyril Fisher. Immunohistochemistry in Diagnosis of Soft Tissue Tumours. Histopathology, Wiley, 2010, 58 (7), pp.1001. 10.1111/j.1365-2559.2010.03707.x. hal-00613811 HAL Id: hal-00613811 https://hal.archives-ouvertes.fr/hal-00613811 Submitted on 6 Aug 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Histopathology Immunohistochemistry in Diagnosis of Soft Tissue Tumours ForJournal: Histopathology Peer Review Manuscript ID: HISTOP-08-10-0420 Wiley - Manuscript type: Review Date Submitted by the 01-Aug-2010 Author: Complete List of Authors: fisher, cyril; royal marsden hospital, histopathology Keywords: soft tissue tumours, immunohistochemistry, sarcoma, diagnosis Published on behalf of the British Division of the International Academy of Pathology Page 1 of 39 Histopathology Immunohistochemistry in Diagnosis of Soft Tissue Tumours For PeerCyril FisherReview Royal Marsden Hospital, London UK Correspondence to: Prof Cyril Fisher MD DSc FRCPath Dept of Histopathology The Royal Marsden Hospital 203 Fulham Road London SW3 6JJ UK Email: [email protected] Tel: +44 207 808 2631 Fax +44 207 808 2578 Running Title : Soft Tissue Tumour Immunohistochemistry Key Words Immunohistochemistry, sarcoma, diagnosis, soft tissue tumour 1 Published on behalf of the British Division of the International Academy of Pathology Histopathology Page 2 of 39 Abstract Immunohistochemistry in soft tissue tumours, and especially sarcomas, is used to identify differentiation in the neoplastic cells.
    [Show full text]